drug-repurposing

Drug repurposing identifies new indications by integrating disease-target associations, drug-target interactions, and safety profiles from multiple knowledge bases to rank and prioritize candidates. This approach enables rapid screening and evidence-based decision-making for experimental validation.

Yes, drug repositioning integrates ChEMBL and OpenTargets alongside DrugBank, DGIdb, FAERS, PubMed, and ClinicalTrials data. Multi-database cross-validation ensures comprehensive evidence mining, structured scoring, and safety filtering for new indications.

The best way to score candidates is through a data-driven scoring system that applies structured ranking and risk filtering across integrated databases. This systematic process prioritizes compounds for experimental validation based on evidence strength and safety profiles.

Drug repurposing supports target-based, compound-based, and disease-driven workflows for rapid screening. These strategies fetch disease targets, pull candidate drugs, score results, and export top indications using cross-database validation and evidence mining.

Safety filtering during drug repurposing leverages FAERS data and safety profiles to remove candidates with adverse risk signals. This systematic risk filtering ensures that only prioritized, safer candidates proceed to experimental validation and downstream decision-making.

Use a disease-driven workflow for drug repurposing when starting from a specific condition to fetch associated targets and pull candidate drugs. Target-based screening is preferable when your research begins with a known molecular target rather than a disease phenotype.